| |
| |
|
| Insider
Information: |
Lyssikatos Joseph P |
| Relationship: |
|
| City: |
Boulder |
| State: |
CO |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
1 |
|
| Direct
Shares |
0 |
|
|
Indirect Shares
|
1,117,035 |
|
|
| Direct
Value |
$0 |
|
|
|
Indirect Value
|
$0 |
|
|
| Total
Shares |
1,117,035 |
|
|
| Total
Value |
$0 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
0
|
|
Stock
price went up :
|
|
|
| Stock
price went down : |
|
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
| Percentage
Gain/Loss : |
0.0%
|
0.0%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Enliven Therapeutics Ord Shs |
ELVN |
|
2024-04-29 |
0 |
2024-04-29 |
1,117,035 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
25 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 1
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| ELVN |
Enliven Therapeutics Ord ... |
CHIEF SCIENTIFIC OFFICER |
• • – |
2024-04-29 |
4 |
AS |
$17.86 |
$214,988 |
D/D |
(12,000) |
0 |
0 |
- |
|
| ELVN |
Enliven Therapeutics Ord ... |
CHIEF SCIENTIFIC OFFICER |
• • – |
2024-04-29 |
4 |
OE |
$1.12 |
$13,440 |
D/D |
12,000 |
12,000 |
0 |
- |
|
| ELVN |
Enliven Therapeutics Ord ... |
CHIEF SCIENTIFIC OFFICER |
• • – |
2024-04-11 |
4 |
AS |
$25.04 |
$751,332 |
D/D |
(30,000) |
0 |
0 |
- |
|
| ELVN |
Enliven Therapeutics Ord ... |
CHIEF SCIENTIFIC OFFICER |
• • – |
2024-04-11 |
4 |
OE |
$1.12 |
$33,600 |
D/D |
30,000 |
30,000 |
0 |
- |
|
| ELVN |
Enliven Therapeutics Ord ... |
CHIEF SCIENTIFIC OFFICER |
• • – |
2024-04-01 |
4 |
AS |
$17.72 |
$223,146 |
D/D |
(12,000) |
0 |
0 |
- |
|
| ELVN |
Enliven Therapeutics Ord ... |
CHIEF SCIENTIFIC OFFICER |
• • – |
2024-04-01 |
4 |
OE |
$1.12 |
$13,440 |
D/D |
12,000 |
12,000 |
0 |
- |
|
| ELVN |
Enliven Therapeutics Ord ... |
CHIEF SCIENTIFIC OFFICER |
• • – |
2024-02-29 |
4 |
OE |
$1.12 |
$13,440 |
D/D |
12,000 |
12,000 |
0 |
- |
|
| ELVN |
Enliven Therapeutics Ord ... |
CHIEF SCIENTIFIC OFFICER |
• • – |
2024-02-29 |
4 |
AS |
$16.30 |
$197,006 |
D/D |
(12,000) |
0 |
0 |
- |
|
| ELVN |
Enliven Therapeutics Ord ... |
CHIEF SCIENTIFIC OFFICER |
• • – |
2024-01-29 |
4 |
AS |
$15.85 |
$190,256 |
D/D |
(12,000) |
0 |
0 |
- |
|
| ELVN |
Enliven Therapeutics Ord ... |
CHIEF SCIENTIFIC OFFICER |
• • – |
2024-01-29 |
4 |
OE |
$1.12 |
$13,440 |
D/D |
12,000 |
12,000 |
0 |
- |
|
| ELVN |
Enliven Therapeutics Ord ... |
Chief Scientific Officer |
• • – |
2023-12-29 |
4 |
AS |
$14.13 |
$171,381 |
D/D |
(12,000) |
0 |
0 |
- |
|
| ELVN |
Enliven Therapeutics Ord ... |
Chief Scientific Officer |
• • – |
2023-12-29 |
4 |
OE |
$1.12 |
$13,440 |
D/D |
12,000 |
12,000 |
0 |
- |
|
| ELVN |
Enliven Therapeutics Ord ... |
Chief Scientific Officer |
• • – |
2023-12-22 |
4 |
AS |
$13.07 |
$85,530 |
D/D |
(6,546) |
0 |
0 |
- |
|
| ELVN |
Enliven Therapeutics Ord ... |
Chief Scientific Officer |
• • – |
2023-12-22 |
4 |
OE |
$1.12 |
$7,332 |
D/D |
6,546 |
6,546 |
0 |
- |
|
| ELVN |
Enliven Therapeutics Ord ... |
Chief Scientific Officer |
• • – |
2023-12-21 |
4 |
AS |
$13.00 |
$260 |
D/D |
(20) |
0 |
0 |
- |
|
| ELVN |
Enliven Therapeutics Ord ... |
Chief Scientific Officer |
• • – |
2023-12-21 |
4 |
OE |
$1.12 |
$22 |
D/D |
20 |
20 |
0 |
- |
|
| ELVN |
Enliven Therapeutics Ord ... |
Chief Scientific Officer |
• • – |
2023-12-20 |
4 |
AS |
$13.01 |
$113,046 |
D/D |
(8,688) |
0 |
0 |
- |
|
| ELVN |
Enliven Therapeutics Ord ... |
Chief Scientific Officer |
• • – |
2023-12-20 |
4 |
OE |
$1.12 |
$9,731 |
D/D |
8,688 |
8,688 |
0 |
- |
|
| ELVN |
Enliven Therapeutics Ord ... |
Chief Scientific Officer |
• • – |
2023-12-19 |
4 |
OE |
$1.12 |
$224 |
D/D |
200 |
200 |
0 |
- |
|
| ELVN |
Enliven Therapeutics Ord ... |
Chief Scientific Officer |
• • – |
2023-12-19 |
4 |
AS |
$13.00 |
$2,600 |
D/D |
(200) |
0 |
0 |
- |
|
| ELVN |
Enliven Therapeutics Ord ... |
Chief Scientific Officer |
• • – |
2023-11-03 |
4 |
AS |
$13.08 |
$111,751 |
D/D |
(8,546) |
0 |
0 |
- |
|
| ELVN |
Enliven Therapeutics Ord ... |
Chief Scientific Officer |
• • – |
2023-11-03 |
4 |
OE |
$1.12 |
$9,572 |
D/D |
8,546 |
8,546 |
0 |
- |
|
| ELVN |
Enliven Therapeutics Ord ... |
Chief Scientific Officer |
• • – |
2023-09-29 |
4 |
AS |
$13.62 |
$163,498 |
D/D |
(12,000) |
0 |
0 |
- |
|
| ELVN |
Enliven Therapeutics Ord ... |
Chief Scientific Officer |
• • – |
2023-09-29 |
4 |
OE |
$1.12 |
$13,440 |
D/D |
12,000 |
12,000 |
0 |
- |
|
| ELVN |
Enliven Therapeutics Ord ... |
Chief Scientific Officer |
• • – |
2023-02-23 |
4 |
A |
$0.00 |
$0 |
I/I |
1,117,035 |
1,117,035 |
0 |
- |
|
25 Records found
|
1
|
Page 1 of 1 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
